Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity
American Journal of Health-System Pharmacy · 05.08.2025 · 82 (16) · 886-890
DOI: 10.1093/ajhp/zxaf088 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 12.04.2025. Verfasst von Britnee Innocent und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Taneja College of Pharmacy, Tampa, FL, USA. Hauptthemen laut MEDLINE: Binge-Eating Disorder, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
Binge eating disorder (BED) is a psychological disorder that poses several functional consequences for those affected. Management of BED centers around psychological and pharmacological treatment modalities, which have been associated with variable efficacy and the potential for severe adverse effects. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), approved by the Food and Drug Administration for conditions such as diabetes and weight management, are an emerging therapy of interest in BED. Summary In this case report, we describe use of dulaglutide for treatment of a patient with BED, obesity, and type 2 diabetes mellitus. The patient’s baseline binge eating scale (BES) score, glycated hemoglobin level, body mass index (BMI), and weight were obtained. Following these baseline assessments, dulaglutide 0.75 mg once weekly was initiated to optimize management of the patient’s type 2 diabetes. Follow-up measurements were obtained 6 weeks after initiation, at which time reductions in the patient’s BES score, BMI, weight, and BED symptoms were observed. Moreover, dulaglutide was well tolerated without adverse drug events.
Conclusion
This case report describes the use of dulaglutide in the management of mild BED in the setting of comorbid type 2 diabetes and obesity. Further research is necessary to evaluate the long-term effectiveness of GLP-1 RAs in the management of BED and to determine the optimal duration and dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of South Florida Taneja College of Pharmacy, Tampa, FL, USA.
- University of New Mexico College of Pharmacy, Albuquerque, NM, USA.
Zitieren
APA
Innocent, B., Elmaoued, A. A., Cowart, K., & White, R. T. (2025). Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity. American Journal of Health-System Pharmacy, 82(16), 886-890. https://doi.org/10.1093/ajhp/zxaf088
Vancouver
Innocent B, Elmaoued AA, Cowart K, White RT. Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity. American Journal of Health-System Pharmacy. 2025;82(16):886-890. doi:10.1093/ajhp/zxaf088
BibTeX
@article{Innocent2025,
author = {Innocent, Britnee and Elmaoued, Amre A and Cowart, Kevin and White, Raechel T},
title = {Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity},
journal = {American Journal of Health-System Pharmacy},
year = {2025},
volume = {82},
number = {16},
pages = {886--890},
doi = {10.1093/ajhp/zxaf088}
}
EUVIMED